Drug intelligence / Profile preview

erythromycin + gentamicin + metronidazole + neomycin

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

This is a combination of four antibiotics—erythromycin, gentamicin, metronidazole, and neomycin—used together primarily for perioperative prophylaxis in colorectal surgery and other gastrointestinal procedures. Each component has a distinct mechanism of action: - Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. - Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. - Metronidazole is a nitroimidazole antibiotic effective against anaerobic bacteria and protozoa; it disrupts DNA structure through reduction in anaerobic cells. - Neomycin is another aminoglycoside that also inhibits bacterial protein synthesis at the 30S ribosomal subunit. This combination targets both aerobic and anaerobic bacteria commonly found in the gut flora. It may be used as part of bowel preparation regimens before colorectal surgery to reduce surgical site infections[1][2][3]. The regimen can involve oral administration (neomycin, erythromycin or metronidazole) combined with intravenous gentamicin or metronidazole[1][2][3].

02

Targets

NeuraminidaseBacterial 50S ribosomal subunitBacterial Ribosome

Beyond the preview

Go deeper on erythromycin + gentamicin + metronidazole + neomycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on erythromycin + gentamicin + metronidazole + neomycin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call